Gregory K. Feld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gregory K. Feld has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- David E. Krummen
Division of Cardiology, Cardiac Electrophysiology, University of California San Diego , Cardiology Section 111A, La Jolla, CA 92161, USA
9 shared publications - Gordon Ho
Division of Cardiology, Cardiac Electrophysiology, University of California San Diego, La Jolla, CA, USA
8 shared publications - Jonathan Chong Hsu
University of California, San Diego
8 shared publications - Farshad Raissi
University of California San Diego
5 shared publications Frederick T. Han
Department of Medicine University of California San Diego La Jolla California USA
4 shared publications- Kurt S. Hoffmayer
University of California-San Diego, La Jolla, California, USA
4 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Artificial intelligence ECG localization facilitates focused activation mapping and improves outcomes in hemodynamically unstable ventricular tachycardia
- 3 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Open AccessArtificial intelligence ECG localization facilitates focused activation mapping and improves outcomes in hemodynamically unstable ventricular tachycardia
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (3) , e013294
Harmonized Definitions and Nomenclature for Use in Pulsed Field Ablation
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (3) , e013294
Harmonized Definitions and Nomenclature for Use in Pulsed Field Ablation
- 16 May 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (7) , 1631-1633
Atypical Left Atrial Flutter After Posterior Wall and Pulmonary Vein Isolation Atrial Fibrillation
- 16 May 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (7) , 1631-1633
Atypical Left Atrial Flutter After Posterior Wall and Pulmonary Vein Isolation Atrial Fibrillation
- Open Access
- 4 March 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (5) , 916-928
Impact of artificial intelligence arrhythmia mapping on time to first ablation, procedure duration, and fluoroscopy use
Introduction: Artificial intelligence (AI) ECG arrhythmia mapping provides arrhythmia source localization using 12‐lead ECG data; whether this information impacts procedural efficiency is unknown. We performed a retrospective, case‐control study to evaluate the hypothesis that AI ECG mapping may reduce time to ablation, procedural duration, and fluoroscopy.Materials and Methods: Cases in which system output was used were retrospectively enrolled according to IRB‐approved protocols at each site. Matched control cases were enrolled in reverse chronological order beginning on the last day for which the technology was unavailable. Controls were matched based upon physician, institution, arrhythmia, and a predetermined complexity rating. Procedural metrics, fluoroscopy data, and clinical outcomes were assessed from time‐stamped medical records.Results: The study group consisted of 28 patients (age 65 ± 11 years, 46% female, left atrial dimension 4.1 ± 0.9 cm, LVEF 50 ± 18%) and was similar to 28 controls. The most common arrhythmia types were atrial fibrillation (n = 10), premature ventricular complexes (n = 8), and ventricular tachycardia (n = 6). Use of the system was associated with a 19.0% reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p = 0.02), a 22.6% reduction in procedure duration (233 ± 51 vs. 301 ± 83 min, p < 0.001), and a 43.7% reduction in fluoroscopy (18.7 ± 13.3 vs. 33.2 ± 18.0 min, p < 0.001) versus controls. At 6 months follow‐up, arrhythmia‐free survival was 73.5% in the study group and 63.3% in the control group (p = 0.56).Conclusion: Use of forward‐solution AI ECG mapping is associated with reductions in time to first ablation, procedure duration, and fluoroscopy without an adverse impact on procedure outcomes or complications.
- 4 March 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (5) , 916-928
Open AccessImpact of artificial intelligence arrhythmia mapping on time to first ablation, procedure duration, and fluoroscopy use
Introduction: Artificial intelligence (AI) ECG arrhythmia mapping provides arrhythmia source localization using 12‐lead ECG data; whether this information impacts procedural efficiency is unknown. We performed a retrospective, case‐control study to evaluate the hypothesis that AI ECG mapping may reduce time to ablation, procedural duration, and fluoroscopy.Materials and Methods: Cases in which system output was used were retrospectively enrolled according to IRB‐approved protocols at each site. Matched control cases were enrolled in reverse chronological order beginning on the last day for which the technology was unavailable. Controls were matched based upon physician, institution, arrhythmia, and a predetermined complexity rating. Procedural metrics, fluoroscopy data, and clinical outcomes were assessed from time‐stamped medical records.Results: The study group consisted of 28 patients (age 65 ± 11 years, 46% female, left atrial dimension 4.1 ± 0.9 cm, LVEF 50 ± 18%) and was similar to 28 controls. The most common arrhythmia types were atrial fibrillation (n = 10), premature ventricular complexes (n = 8), and ventricular tachycardia (n = 6). Use of the system was associated with a 19.0% reduction in time to ablation (133 ± 48 vs. 165 ± 49 min, p = 0.02), a 22.6% reduction in procedure duration (233 ± 51 vs. 301 ± 83 min, p < 0.001), and a 43.7% reduction in fluoroscopy (18.7 ± 13.3 vs. 33.2 ± 18.0 min, p < 0.001) versus controls. At 6 months follow‐up, arrhythmia‐free survival was 73.5% in the study group and 63.3% in the control group (p = 0.56).Conclusion: Use of forward‐solution AI ECG mapping is associated with reductions in time to first ablation, procedure duration, and fluoroscopy without an adverse impact on procedure outcomes or complications.
- Open Access
- 25 August 2023
- Published by Wiley
Use of Computational ECG Mapping to Guide Successful Surgical Cryoablation of a PVC Originating near an Intramural Anomalous Coronary Artery
Introduction: Premature ventricular contractions (PVC) and anomalous coronary arteries have not been previously associated. Methods: 40-year-old female presented with symptomatic PVCs. Pre-ablation imaging revealed an anomalous right coronary artery (RCA) originating from the left coronary cusp with an interarterial, intramural course. Novel ECG mapping localized PVCs to the septal right ventricular outflow tract (RVOT) near the anomalous RCA. Results: Surgical PVC cryoablation at the endocardial RVOT was performed, followed by unroofing surgery, with Conclusion : This is the first report associating PVCs to the site of an anomalous RCA. Surgical cryoablation during unroofing surgery was guided by novel ECG mapping.
- 25 August 2023
- Published by Wiley
Open AccessUse of Computational ECG Mapping to Guide Successful Surgical Cryoablation of a PVC Originating near an Intramural Anomalous Coronary Artery
Introduction: Premature ventricular contractions (PVC) and anomalous coronary arteries have not been previously associated. Methods: 40-year-old female presented with symptomatic PVCs. Pre-ablation imaging revealed an anomalous right coronary artery (RCA) originating from the left coronary cusp with an interarterial, intramural course. Novel ECG mapping localized PVCs to the septal right ventricular outflow tract (RVOT) near the anomalous RCA. Results: Surgical PVC cryoablation at the endocardial RVOT was performed, followed by unroofing surgery, with Conclusion : This is the first report associating PVCs to the site of an anomalous RCA. Surgical cryoablation during unroofing surgery was guided by novel ECG mapping.
- Open Access
- 25 October 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (10) , 2124-2133
Combined pulsed field ablation with ultra‐low temperature cryoablation: A preclinical experience
Background: Combining pulsed field ablation (PFA) with ultra‐low temperature cryoablation (ULTC) represents a novel energy source which may create more transmural cardiac lesions. We sought to assess the feasibility of lesions created by combined cryoablation and pulsed field ablation (PFCA) versus PFA alone.Methods: Ablations were performed using a custom PFA generator, ULTC console, and an ablation catheter with insertable stylets. PFA was delivered in a biphasic, bipolar train. PFCA precooled the tissue for 30 s followed by a concurrent PFA train. Benchtop testing using Schlieren imaging and microbubble volume assessment were used to compare PFA and PFCA. PFA and PFCA lesions using pre‐optimized and optimized ablation protocols were studied in 6 swine. Pre and post‐ECGs were recorded for each ablation and a gross necropsy was performed at 14 days.Results: Consistent with benchtop comparisons of heat and microbubble generation, PFA deliveries in the animals were accompanied by muscle contractions and significant microbubbles (Grade 2–3) visible on intracardiac echo while neither occurred during PFCA at higher voltage levels. Both PFA and PFCA acutely eliminated or highly attenuated (>80%) local atrial electrograms. Histology of PFA and PFCA lesions indicated depth up to 6–7 mm and nearly all lesions were transmural. Optimized PFCA produced wider cavotricuspid isthmus lesions with evidence of tissue selectivity.Conclusion: A novel technology combining PFA and ULTC into one energy source demonstrated in‐vivo feasibility for PFCA ablation. PFCA had a more favorable thermal profile and did not produce muscle contraction or microbubbles while extending lesion depth beyond cryoablation.
- 25 October 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (10) , 2124-2133
Open AccessCombined pulsed field ablation with ultra‐low temperature cryoablation: A preclinical experience
Background: Combining pulsed field ablation (PFA) with ultra‐low temperature cryoablation (ULTC) represents a novel energy source which may create more transmural cardiac lesions. We sought to assess the feasibility of lesions created by combined cryoablation and pulsed field ablation (PFCA) versus PFA alone.Methods: Ablations were performed using a custom PFA generator, ULTC console, and an ablation catheter with insertable stylets. PFA was delivered in a biphasic, bipolar train. PFCA precooled the tissue for 30 s followed by a concurrent PFA train. Benchtop testing using Schlieren imaging and microbubble volume assessment were used to compare PFA and PFCA. PFA and PFCA lesions using pre‐optimized and optimized ablation protocols were studied in 6 swine. Pre and post‐ECGs were recorded for each ablation and a gross necropsy was performed at 14 days.Results: Consistent with benchtop comparisons of heat and microbubble generation, PFA deliveries in the animals were accompanied by muscle contractions and significant microbubbles (Grade 2–3) visible on intracardiac echo while neither occurred during PFCA at higher voltage levels. Both PFA and PFCA acutely eliminated or highly attenuated (>80%) local atrial electrograms. Histology of PFA and PFCA lesions indicated depth up to 6–7 mm and nearly all lesions were transmural. Optimized PFCA produced wider cavotricuspid isthmus lesions with evidence of tissue selectivity.Conclusion: A novel technology combining PFA and ULTC into one energy source demonstrated in‐vivo feasibility for PFCA ablation. PFCA had a more favorable thermal profile and did not produce muscle contraction or microbubbles while extending lesion depth beyond cryoablation.
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (9) , 595-608
Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study
Background: The accuracy of noninvasive arrhythmia source localization using a forward-solution computational mapping system has not yet been evaluated in blinded, multicenter analysis. This study tested the hypothesis that a computational mapping system incorporating a comprehensive arrhythmia simulation library would provide accurate localization of the site-of-origin for atrial and ventricular arrhythmias and pacing using 12-lead ECG data when compared with the gold standard of invasive electrophysiology study and ablation. Methods: The VMAP study (Vectorcardiographic Mapping of Arrhythmogenic Probability) was a blinded, multicenter evaluation with final data analysis performed by an independent core laboratory. Eligible episodes included atrial and ventricular: tachycardia, fibrillation, pacing, premature atrial and ventricular complexes, and orthodromic atrioventricular reentrant tachycardia. Mapping system results were compared with the gold standard site of successful ablation or pacing during electrophysiology study and ablation. Mapping time was assessed from time-stamped logs. Prespecified performance goals were used for statistical comparisons. Results: A total of 255 episodes from 225 patients were enrolled from 4 centers. Regional accuracy for ventricular tachycardia and premature ventricular complexes in patients without significant structural heart disease (n=75, primary end point) was 98.7% (95% CI, 96.0%–100%; P 0 P 0 P 0 <0.70). Median spatial accuracy was 15 mm (n=255, interquartile range, 7–25 mm). The mapping process was completed in a median of 0.8 minutes (interquartile range, 0.4–1.4 minutes). Conclusions: Computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. Spatial accuracy analysis demonstrated clinically actionable results. This rapid, noninvasive mapping technology may facilitate catheter-based and noninvasive targeted arrhythmia therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04559061.
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (9) , 595-608
Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study
Background: The accuracy of noninvasive arrhythmia source localization using a forward-solution computational mapping system has not yet been evaluated in blinded, multicenter analysis. This study tested the hypothesis that a computational mapping system incorporating a comprehensive arrhythmia simulation library would provide accurate localization of the site-of-origin for atrial and ventricular arrhythmias and pacing using 12-lead ECG data when compared with the gold standard of invasive electrophysiology study and ablation. Methods: The VMAP study (Vectorcardiographic Mapping of Arrhythmogenic Probability) was a blinded, multicenter evaluation with final data analysis performed by an independent core laboratory. Eligible episodes included atrial and ventricular: tachycardia, fibrillation, pacing, premature atrial and ventricular complexes, and orthodromic atrioventricular reentrant tachycardia. Mapping system results were compared with the gold standard site of successful ablation or pacing during electrophysiology study and ablation. Mapping time was assessed from time-stamped logs. Prespecified performance goals were used for statistical comparisons. Results: A total of 255 episodes from 225 patients were enrolled from 4 centers. Regional accuracy for ventricular tachycardia and premature ventricular complexes in patients without significant structural heart disease (n=75, primary end point) was 98.7% (95% CI, 96.0%–100%; P 0 P 0 P 0 <0.70). Median spatial accuracy was 15 mm (n=255, interquartile range, 7–25 mm). The mapping process was completed in a median of 0.8 minutes (interquartile range, 0.4–1.4 minutes). Conclusions: Computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. Spatial accuracy analysis demonstrated clinically actionable results. This rapid, noninvasive mapping technology may facilitate catheter-based and noninvasive targeted arrhythmia therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04559061.
- 22 March 2022
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 65 (3) , 583-584
Editorial Commentary — “Clinical characteristics and long-term outcomes of catheter ablation in young adults with atrial fibrillation”
- 22 March 2022
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 65 (3) , 583-584
Editorial Commentary — “Clinical characteristics and long-term outcomes of catheter ablation in young adults with atrial fibrillation”
- 21 March 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (3) , 377-379
Alternative Approaches for Ablation of the Mitral Isthmus for Treatment of Atrial Fibrillation
- 21 March 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (3) , 377-379
Alternative Approaches for Ablation of the Mitral Isthmus for Treatment of Atrial Fibrillation